Transforming Growth Factor Beta 1 (TGFB1) – Drugs in Development, 2021

Transforming Growth Factor Beta 1 (TGFB1) – Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.

Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 34 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 8, 1, 11 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Dermatology, Infectious Disease, Cardiovascular, Central Nervous System, Genetic Disorders, Hematological Disorders and Male Health which include indications Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Diabetic Nephropathy, Fibrosis, Hepatocellular Carcinoma, Kidney Fibrosis, Myelofibrosis, Bladder Cancer, Breast Cancer, Corneal Dystrophy, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Primary Sclerosing Cholangitis, Squamous Cell Carcinoma, Systemic Sclerosis (Scleroderma), Acute Respiratory Distress Syndrome, Age Related Macular Degeneration, Anemia, Basal Cell Carcinoma (Basal Cell Epithelioma), Benign Prostatic Hyperplasia, Bone Disorders, Cholangitis, Choroidal Neovascularization, Colitis, Colorectal Cancer, Focal Segmental Glomerulosclerosis (FSGS), Glaucoma, Gynecological Cancer, Head And Neck Cancer, Hyperalgesia, Hypertrophic Scars, Inflammation, Interstitial Lung Fibrosis, Keloids, Knee Osteoarthritis, Lung Adenocarcinoma, Melanoma, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteoarthritis, Osteogenesis Imperfecta, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatitis Pain, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension, Scar, Transitional Cell Cancer (Urothelial Cell Cancer), Triple-Negative Breast Cancer (TNBC) and Unspecified Cancer.

The latest report Transforming Growth Factor Beta 1 – Drugs in Development, 2021, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 1 (TGFB1)

– The report reviews Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 1 (TGFB1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 1 (TGFB1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AiViva BioPharma Inc

Avacta Life Sciences Ltd

Avellino Lab USA Inc

Bonac Corp

Bristol-Myers Squibb Co

Certa Therapeutics Pty Ltd

Ensol Biosciences Inc

Genoscience Pharma

Genzyme Corp

Guangzhou Nanxin Pharmaceutical Co Ltd

Huabo Biopharm Co Ltd

Isarna Therapeutics GmbH

Johnson & Johnson

Nanjing Shenghe Pharmaceutical Co Ltd

Novartis AG

Phio Pharmaceuticals Corp

Scholar Rock Inc

Sirnaomics Inc

Sisaf Ltd

Table of Contents

Table of Contents

Introduction

Transforming Growth Factor Beta 1 (TGFB1) - Overview

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Development

Transforming Growth Factor Beta 1 (TGFB1) - Therapeutics Assessment

Transforming Growth Factor Beta 1 (TGFB1) - Companies Involved in Therapeutics Development

Transforming Growth Factor Beta 1 (TGFB1) - Drug Profiles

Transforming Growth Factor Beta 1 (TGFB1) - Dormant Products

Transforming Growth Factor Beta 1 (TGFB1) - Discontinued Products

Transforming Growth Factor Beta 1 (TGFB1) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Indications, 2021 (Contd..1)

Number of Products under Development by Indications, 2021 (Contd..2)

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Products under Development by Companies, 2021 (Contd..3)

Products under Development by Companies, 2021 (Contd..4)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by AiViva BioPharma Inc, 2021

Pipeline by Avacta Life Sciences Ltd, 2021

Pipeline by Avellino Lab USA Inc, 2021

Pipeline by Bonac Corp, 2021

Pipeline by Bristol-Myers Squibb Co, 2021

Pipeline by Certa Therapeutics Pty Ltd, 2021

Pipeline by Ensol Biosciences Inc, 2021

Pipeline by Genoscience Pharma, 2021

Pipeline by Genzyme Corp, 2021

Pipeline by Guangzhou Nanxin Pharmaceutical Co Ltd, 2021

Pipeline by Huabo Biopharm Co Ltd, 2021

Pipeline by Isarna Therapeutics GmbH, 2021

Pipeline by Johnson & Johnson, 2021

Pipeline by Nanjing Shenghe Pharmaceutical Co Ltd, 2021

Pipeline by Novartis AG, 2021

Pipeline by Phio Pharmaceuticals Corp, 2021

Pipeline by Scholar Rock Inc, 2021

Pipeline by Sirnaomics Inc, 2021

Pipeline by Sisaf Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Dormant Products, 2021 (Contd..2)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports